In This Article:
-
Revenue: $951 million, representing a 0.5% increase on a reported basis and 1.3% on an organic basis compared to the prior year quarter.
-
Organic Sales Growth: 1.3%, driven by timing of EDS sales with distributors.
-
Adjusted EPS: $0.5, up 3% versus the prior year quarter.
-
Operating Cash Flow: $141 million, up 5% compared to the prior year quarter.
-
Share Repurchases: $100 million completed in Q3, with a year-to-date total of $345 million returned to shareholders.
-
Leverage Ratio: Increased slightly to 2.8 times.
-
Organic Sales Decline (Excluding Timing Impacts): 0.8%.
-
Gross Margin: Declined 40 basis points versus prior year due to unfavorable product mix and lower volume.
-
Segment Performance - Essential Dental Solutions: Organic sales increased 7.5%.
-
Segment Performance - Orthodontic and Implant Solutions: Organic sales declined 3.9%.
-
Segment Performance - Connected Technology Solutions: Organic sales declined 1.4% versus the prior year quarter.
-
Regional Performance - US: Organic sales increased 5.1%.
-
Regional Performance - Europe: Organic sales declined 2%.
-
Regional Performance - Rest of World: Organic sales grew 0.6%.
-
Full Year 2024 Outlook - Organic Sales: Expected to be down 2.5% to 3.5%.
-
Full Year 2024 Outlook - Net Sales: Expected to be in the range of $3.79 billion to $3.82 billion.
-
Full Year 2024 Outlook - Adjusted EBITDA Margin: Approximately 17.5%.
-
Full Year 2024 Outlook - Adjusted EPS: Expected to be in the range of $1.82 to $1.86.
Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Dentsply Sirona Inc (NASDAQ:XRAY) reported $951 million in revenue for Q3 2024, with organic sales up 1.3%, driven by timing of EDS sales.
-
The launch of Primescan 2 in September contributed to growth in the CAD/CAM segment, marking a milestone in digital dentistry.
-
The company successfully launched Exmark Pro Plus in the US, exceeding full-year projections by the end of Q3.
-
Dentsply Sirona Inc (NASDAQ:XRAY) has executed over 70% of its phase two transformation activities, aiming for full run-rate savings by the end of 2025.
-
The company has made significant progress in its ERP rollout, with successful deployments in the UK and the US, enhancing operational efficiency.
Negative Points
-
Dentsply Sirona Inc (NASDAQ:XRAY) announced a voluntary suspension of sales, marketing, and shipments of byte aligners and impression kits due to regulatory reviews, impacting revenue.
-
The company recorded a $500 million non-cash after-tax charge related to goodwill in the orthodontic and implant solution segment due to macroeconomic pressures.
-
Organic sales in the orthodontic and implant solution segment declined by 3.9%, with a notable decline in the US and Europe.
-
The company revised its full-year 2024 outlook, expecting organic sales to be down 2.5% to 3.5%, citing market pressures and challenges with byte.
-
Dentsply Sirona Inc (NASDAQ:XRAY) is facing ongoing macroeconomic challenges, including high interest rates and reduced patient traffic in key markets like Japan and China.